GlobeNewsWire
05 Jul 2026, 13:49 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Grail's NHS-Galleri trial failed to observe its primary endpoint of a statistically significant reduction in Stage III & IV cancers. — Failure of a primary clinical endpoint for a flagship product is a fundamental negative for a biotech company's valuation and commercial prospects.
-0.90A federal securities class action lawsuit has been filed against Grail alleging the company made false and misleading statements regarding the NHS-Galleri trial. — Class action lawsuits introduce significant legal risk and potential financial liabilities, though they often follow the initial price drop.
-0.40Grail's common stock price declined by approximately 50.55% in a single day following the announcement of the trial results on February 19, 2026. — This confirms the market's severe negative reaction to the trial failure, though the move has already occurred.
-0.20Which stocks this story touches
Continue reading
6 related stories
Top 3 movers · tap to explore
The company is facing a federal securities class action lawsuit following a 50% stock price crash and failure to meet a primary clinical trial endpoint.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
2h ago
